KFKimberly L. Fiock

Kimberly L. Fiock

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kimberly L. Fiock has a total of 91 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Feasibility of Craniofacial Vascular Lymph Node Transfer for Augmented Glymphatic Drainage in Rodents

    by Brian T. Andrews, Mario Zanaty, Samantha R. Pierson, Kimberly L. Fiock, Matthew A. Howard, Marlan R. Hansen, Terry C. Yin

    Objective: Glymphatic dysfunction contributes to CNS pathobiology, including neurodegeneration. We hypothesized that vascularized lymph node transfer (VLNT) augments CSF-interstitial solute clearance and could be translated as a surgical therapy analogous to lymphedema surgery. Design: Twenty Long-Evans rats were randomized to 3 arms: (1) Craniectomy Control (hemi-craniectomy; VLNT sampled in situ, nontransposed), (2) VLNT Control (intact calvarium; VLNT without craniectomy), and (3) Experimental (hemi-craniectomy + VLNT). One week postsurgery, Evans Blue dye (EBD) was injected into the cisterna magna; at 4 h, right/left cerebrum and cerebellum lysates underwent spectrophotometry at 608 nm. VLNT viability was verified by podoplanin (PDPN) immunohistochemistry. Main Outcome Measure(s): Two-way ANOVA showed significantly reduced EBD in Experimental vs controls: left hemisphere vs Craniectomy Control P = .0011 and vs VLNT Control P = .0200; cerebellum vs both controls P < .0001. The right hemisphere was lower vs Craniectomy Control ( P = .0255) and not different from VLNT Control ( P = .3878). VLNT-tissue lysates were higher in Experimental than Craniectomy Control ( P = .0028) and VLNT Control ( P = .0289), consistent with active lymphatic uptake. PDPN staining confirmed robust lymphatic endothelial labeling in cross-sectional and longitudinal planes. Results: VLNT significantly enhances putative glymphatic efflux following decompressive craniectomy, recapitulating the therapeutic principle of lymphatic bypass in lymphedema. Conclusion: These proof-of-concept data support VLNT as a candidate surgical intervention for glymphatic insufficiency and neurodegenerative (ND)-relevant proteostasis/clearance failure. Future studies will optimize timing, node vascularization strategies, and longitudinal outcome measures.

  • Open Access

    Robust volumetric multiplex staining of centimeter-scale FFPE tissues guided by neural network-based optimization

    by Ya-Hui Lin, Chao-Yin Huang, Yin-Hsu Chen, Yen-Hui Chen, Ping-Liang Ko, Heng-Hua Hsu, Yi-Chung Tung, Yu-Fang Chen, Hui-Chi Chen, Ann-Shyn Chiang, et al.

    Neurodegenerative diseases involve structural and morphological alterations in tissue architecture that are difficult to capture in single thin sections. Three-dimensional multiplexed pathology, however, remains limited by the lack of clearing methods applicable to formalin-fixed paraffin-embedded (FFPE) clinical specimens. As the development of tissue-clearing methods requires the optimization of multiple parameters, we employed a neural network-based Complex System Response (CSR) approach to guide the design of FIDELITY, an epoxy-free delipidation and epitope-retrieval pipeline for whole FFPE specimens. FIDELITY preserves tissue rigidity, enhances immunostaining efficiency, and supports at least five rounds of multiplex labeling without deformation. It enables whole-brain atlas registration, quantitative neuronal profiling, and volumetric pathology of archived human Alzheimer’s and glioma specimens while remaining compatible with routine histology. Altogether, FIDELITY provides accurate 3D metrics and offers translational potential to bridge spatial mapping and conventional pathology.


  • Top Cited Papers
    Open Access

    Repeated head trauma causes neuron loss and inflammation in young athletes

    by Morgane L. M. D. Butler, Nida Pervaiz, Kerry Breen, Samantha Calderazzo, Petra Ypsilantis, Yichen Wang, Julia Cammasola Breda, Sarah Mazzilli, Raymond Nicks, Elizabeth Spurlock, et al.

    Repetitive head impacts (RHIs) sustained from contact sports are the largest risk factor for chronic traumatic encephalopathy (CTE) 1–4 . Currently, CTE can only be diagnosed after death and the events that trigger initial hyperphosphorylated tau (p-tau) deposition remain unclear 2 . Furthermore, the symptoms endorsed by young individuals are not fully explained by the extent of p-tau deposition 2 , severely hampering therapeutic interventions. Here we observed a multicellular response prior to the onset of CTE p-tau pathology that correlates with number of years of RHI exposure in young people (less than 51 years of age) with RHI exposure, the majority of whom played American football. Leveraging single-nucleus RNA sequencing of tissue from 8 control individuals, 9 RHI-exposed individuals and 11 individuals with low-stage CTE, we identify SPP1-expressing inflammatory microglia, angiogenic and inflamed endothelial cells, astrocytosis and altered synaptic gene expression in those exposed to RHI. We also observe a significant loss of cortical sulcus layer 2/3 neurons independent of p-tau pathology. Finally, we identify TGFβ1 as a potential signal that mediates microglia–endothelial cell cross talk. These results provide robust evidence that multiple years of RHI is sufficient to induce lasting cellular alterations that may underlie p-tau deposition and help explain the early pathogenesis in young former contact sport athletes. Furthermore, these data identify specific cellular responses to RHI that may direct future identification of diagnostic and therapeutic strategies for CTE.


  • Tau pathology in the dorsal raphe may be a prodromal indicator of Alzheimer’s disease

    by Samantha R. Pierson, Kimberly L. Fiock, Ruixiang Wang, Nagalakshmi Balasubramanian, Jessica Reinhardt, Kanza M. Khan, Thomas D. James, Mikayla L. Hunter, Benjamin J. Cooper, Hannah R. Williamsen, et al.

    Protein aggregation in brainstem nuclei is thought to occur in the early stages of Alzheimer’s disease (AD), but its specific role in driving prodromal symptoms and disease progression is largely unknown. The dorsal raphe nucleus (DRN) contains a large population of serotonin (5-hydroxytryptamine; 5-HT) neurons that regulate mood, reward-related behavior, and sleep, which are all disrupted in AD. We report here that tau pathology is present in the DRN of individuals 25–80 years old without a known history of dementia, and its prevalence was comparable to the locus coeruleus (LC). By comparison, fewer cases were positive for other pathological proteins including α-synuclein, β-amyloid, and TDP-43. To evaluate how early tau pathology impacts behavior, we overexpressed human P301L-tau in the DRN of mice and observed depressive-like behaviors and hyperactivity without deficits in spatial memory. Tau pathology was predominantly found in neurons relative to glia and colocalized with a significant proportion of Tph2-expressing neurons in the DRN. 5-HT neurons were also hyperexcitable in P301L-tauDRN mice, and there was an increase in the amplitude of excitatory post-synaptic currents (EPSCs). Moreover, astrocytic density was elevated in the DRN and accompanied by an increase in IL-1α and Frk expression, which suggests increased inflammatory signaling. Additionally, tau pathology was detected in axonal processes in the thalamus, hypothalamus, amygdala, and caudate putamen. A significant proportion of this tau pathology colocalized with the serotonin reuptake transporter (SERT), suggesting that tau may spread in an anterograde manner to regions outside the DRN. Together these results indicate that tau pathology accumulates in the DRN in a subset of individuals over 50 years and may lead to behavioral dysregulation, 5-HT neuronal dysfunction, and activation of local astrocytes which may be prodromal indicators of AD.


  • Open Access

    Repetitive head impacts induce neuronal loss and neuroinflammation in young athletes

    by Morgane L.M.D. Butler, Nida Pervaiz, Kerry Breen, Samantha Calderazzo, Petra Ypsilantis, Yichen Wang, Julia Cammasola Breda, Sarah Mazzilli, Raymond Nicks, Elizabeth Spurlock, et al.

    Repetitive head impacts (RHI) sustained from contact sports are the largest risk factor for chronic traumatic encephalopathy (CTE). Currently, CTE can only be diagnosed after death and the multicellular cascade of events that trigger initial hyperphosphorylated tau (p-tau) deposition remain unclear. Further, the symptoms endorsed by young individuals with early disease are not fully explained by the extent of p-tau deposition, severely hampering development of therapeutic interventions. Here, we show that RHI exposure associates with a multicellular response in young individuals (<51 years old) prior to the onset of CTE p-tau pathology that correlates with number of years of RHI exposure. Leveraging single nucleus RNA sequencing of tissue from 8 control, 9 RHI-exposed, and 11 low stage CTE individuals, we identify SPP1+ inflammatory microglia, angiogenic and inflamed endothelial cell profiles, reactive astrocytes, and altered synaptic gene expression in excitatory and inhibitory neurons in all individuals with exposure to RHI. Surprisingly, we also observe a significant loss of cortical sulcus layer 2/3 neurons in contact sport athletes compared to controls independent of p-tau pathology. Finally, we identify TGFB1 as a potential signal mediating microglia-endothelial cell cross talk through ligand-receptor analysis. These results provide robust evidence that multiple years of RHI exposure is sufficient to induce lasting cellular alterations that may underlie p-tau deposition and help explain the early pathogenesis in young former contact sport athletes. Furthermore, these data identify specific cellular responses to repetitive head impacts that may direct future identification of diagnostic and therapeutic strategies for CTE.


  • Open Access

    Neurohistopathological Findings of the Brain Parenchyma After Long-Term Deep Brain Stimulation: Case Series and Systematic Literature Review

    by Juan Vivanco-Suarez, Timothy Woodiwiss, Kimberly L. Fiock, Marco M. Hefti, Nandakumar S. Narayanan, Jeremy D. W. Greenlee

    Introduction: The efficacy of deep brain stimulation (DBS) has been established to treat several movement and psychiatric disorders. However, several aspects, such as the mechanism of action and tissue changes after treatment are incompletely described. Hence, we aimed to describe the neurohistopathological findings of 9 patients who underwent DBS for movement disorders. Additionally, we performed a systematic literature review on postmortem studies after DBS implantation. Methods: We performed a retrospective study of patients who underwent DBS for movement disorders between 2000-2023 and had postmortem autopsy. Demographics, clinical features, and outcomes were collected. Levodopa equivalent daily dose (LEDD) and total electrical energy delivered (TEED) were calculated. Neurohistopathological assessments were performed from autopsies. A systematic literature review was conducted to summarize the literature. Results: Postmortem neurohistopathologic assessment of 9 patients who underwent DBS for movement disorders (8 Parkinson’s disease [multiple system atrophy was final diagnosis in 1], and 1 parkinsonism) was performed. Median age at DBS implantation was 65 years (range, 54-69), and most were male (8 patients, 89%). Most common DBS target was the subthalamic nucleus (8 patients, 89%). Median DBS duration was 65 months (range, 7-264 months). Post-DBS reduction in LEDD was found in 7/9 patients, and TEED was increased over time in 5/7 patients. No patients died due to DBS. Neurohistopathological assessment showed gliosis in 7 (78%) patients and activated microglial infiltration in 1 (11%). Additionally, postmortem findings (after DBS) of 59 patients (between 1977-2021) were identified in the literature: 26 (44%) for Parkinson’s disease, 20 (34%) for pain, and 13 (22%) for other conditions. Conclusion: Our findings confirm the presence of a local tissue reaction, including gliosis and activated microglial infiltration around the implanted DBS electrodes. The effect of the local changes on the clinical efficacy of DBS is not established. Further DBS postmortem studies and standardization of tissue processing are needed.

  • Open Access

    The Slides I Carry

    by Kimberly L. Fiock


  • Open Access

    Determinants of astrocytic pathology in stem cell models of primary tauopathies

    by Kimberly L. Fiock, Jordan N. Hook, Marco M. Hefti

    Astrocytic tau aggregates are seen in several primary and secondary tauopathies, including progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and chronic traumatic encephalopathy (CTE). In all of these diseases, astrocytic tau consists mostly of the longer (4R) tau isoform, even when adjacent neuronal aggregates consist of a mixture of 3- and 4R tau, as in CTE. Even the rare astrocytic tau aggregates seen in Pick’s disease appear to contain both 3R and 4R tau. The reasons for this, and the mechanisms by which astrocytic tau aggregates form, remain unclear. We used a combination of RNA in situ hybridization and immunofluorescence in post-mortem human brain tissue, as well as tau uptake studies in human stem cell-derived astrocytes, to determine the origins of astrocytic tau in 4R tauopathies. We found no differences in tau mRNA expression between diseases or between tau positive and negative astrocytes within PSP. We then found that stem cell-derived astrocytes preferentially take up long isoform (4R) recombinant tau and that this uptake is impaired by induction of reactivity with inflammatory stimuli or nutritional stress. Astrocytes exposed to either 3R or 4R tau also showed downregulation of genes related to astrocyte differentiation. Our findings suggest that astrocytes preferentially take up neuronal 4R tau from the extracellular space, potentially explaining why 4R tau is the predominant isoform in astrocytic tau aggregates.


  • Open Access

    Determinants of Astrocytic Pathology in Stem Cell Models of Primary Tauopathies

    by Kimberly L. Fiock, Jordan Hook, Marco M. Hefti

    Astrocytic tau aggregates are seen in several primary and secondary tauopathies, including progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and chronic traumatic encephalopathy (CTE). In all cases, astrocytic tau consists exclusively of the longer (4R) tau isoform, even when adjacent neuronal aggregates consist of a mixture of 3- and 4R tau, as in CTE. The reasons for this and the mechanisms by which astrocytic tau aggregates form remain unclear. We used a combination of RNA in situ hybridization and immunofluorescence in post-mortem human brain tissue, as well as tau uptake studies in human stem cell-derived astrocytes, to determine the origins of astrocytic tau in 4R tauopathies. We found that astrocytes across tauopathies do not upregulate tau mRNA expression between diseases or between tau-positive and -negative astrocytes within PSP. We then found that stem cell-derived astrocytes preferentially take up long isoform (4R) labeled recombinant tau and that this uptake is impaired by induction of reactivity with inflammatory stimuli or nutritional stress. Astrocytes exposed to either 3R or 4R tau also showed downregulation of genes related to astrocyte differentiation. Our findings suggest that astrocytes preferentially take up neuronal 4R tau from the extracellular space, which potentially explains why astrocytic tau aggregates contain only 4R tau, and that tau uptake is impaired by decreased nutrient availability or neuroinflammation, both of which are common in the aging brain.


  • Open Access

    Characterization of the Tau Interactome in Human Brain Reveals Isoform-Dependent Interaction with 14-3-3 Family Proteins

    by Ryan K. Betters, Emma Luhmann, Amy C. Gottschalk, Zhen Xu, Mallory R. Shin, Christopher P. Ptak, Kimberly L. Fiock, Lilliana C. Radoshevich, Marco M. Hefti

    Despite exhibiting tau phosphorylation similar to Alzheimer’s disease (AD), the human fetal brain is remarkably resilient to tau aggregation and toxicity. To identify potential mechanisms for this resilience, we used co-immunoprecipitation (co-IP) with mass spectrometry to characterize the tau interactome in human fetal, adult, and Alzheimer’s disease brains. We found significant differences between the tau interactome in fetal and AD brain tissue, with little difference between adult and AD, although these findings are limited by the low throughput and small sample size of these experiments. Differentially interacting proteins were enriched for 14-3-3 domains, and we found that the 14-3-3-β, η, and γ isoforms interacted with phosphorylated tau in Alzheimer’s disease but not the fetal brain. Since long isoform (4R) tau is only seen in the adult brain and this is one of the major differences between fetal and AD tau, we tested the ability of our strongest hit (14-3-3-β) to interact with 3R and 4R tau using co-immunoprecipitation, mass photometry, and nuclear magnetic resonance (NMR). We found that 14-3-3-β interacts preferentially with phosphorylated 4R tau, forming a complex consisting of two 14-3-3-β molecules to one tau. By NMR, we mapped 14-3-3 binding regions on tau that span the second microtubule binding repeat, which is unique to 4R tau. Our findings suggest that there are isoform-driven differences between the phospho-tau interactome in fetal and Alzheimer’s disease brain, including differences in interaction with the critical 14-3-3 family of protein chaperones, which may explain, in part, the resilience of fetal brain to tau toxicity.